Synageva gains orphan-drug status for enzyme-replacement therapy

07/7/2010 | Boston Globe (tiered subscription model), The

The FDA granted orphan-drug designation to SBC-102, Synageva BioPharma's enzyme-replacement therapy. The drug candidate is being developed as a treatment for lysosomal acid lipase deficiency, a rare disorder for which there is no approved treatment.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA